Schilke Tobin 4
4 · Revance Therapeutics, Inc. · Filed Mar 4, 2024
Insider Transaction Report
Form 4
Transactions
- Award
Common Stock
2024-02-29+17,447→ 205,849 total
Footnotes (1)
- [F1]Represents the vesting of performance-based restricted stock units (PSUs) granted on January 31, 2023, which vest over a three-year period based on the achievement of revenue goals. On February 29, 2024, the Issuer's Compensation Committee certified a portion of the PSUs eligible to vest based on (i) the achievement of a revenue goal, measured beginning January 1, 2023 through December 31, 2023, and (ii) subject to the Reporting Person remaining in continuous service through the vesting date of March 15, 2024.